8:00 - 8:15 am  Welcome and Approval of 2018 Spring Meeting Minutes  T. Petrella

8:15 - 8:45 am  Rapid Trial Updates (awaiting analysis, recently closed, previously approved proposals)

- MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG)  T. Petrella

- MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG)  T. Petrella

- ME14 - Prophylactic mesalamine to reduce immune-related AEs with combination ipilimumab / nivolumab in metastatic melanoma  T. Petrella

- MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance)  M. Butler

- IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases  T. Petrella

- ME.15 - Melanoma Margins Trial (MelMarT) II: A Phase III multi-centre, randomised controlled trial investigating 1 cm vs 2 cm wide excision margins for AJCC stage II primary cutaneous melanoma  F. Wright

8:45 - 9:30 am  Trial Updates (ongoing / planned)

- ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP)  T. Baetz/ X. Song
9:30 – 9:45 am    Report from IND         J. Dancey

9:45 - 10:00 am    Break

10:00 - 12:00 pm   New Proposals / Working Group Updates
                   • Surgical Working Group                  F. Wright
                   • Neo-Adjuvant Working Group                X. Song
                   • Adjuvant Working Group                   S. Ernst / R. Jamal
                   • Metastatic Working Group                 M. Ong / T. Baetz
                   • Surveillance Working Group               C. Nessim
                   • IND proposal                              M. Ong

12:00 pm          Meeting Adjourned

12:00 - 1:00 pm  Executive Committee meeting to follow (closed)